Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Nov 15, 2022: Acerus Reports Third Quarter 2022 Financial Results
Aug 23, 2022: Acerus Announces Resignation of CFO Effective November 20, 2022
Aug 09, 2022: Acerus Reports Second Quarter 2022 Financial Results
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets, and distributes novel innovative branded products. It focuses in the therapeutic areas of women’s health (female sexual dysfunction, hormone replacement therapy) and men’s health (urology). The company’s marketed products include Estrace, for menopausal symptom,s and Natesto, testosterone for male hypogonadism. Acerus pipeline products include Tefina, Avanafil, Elegant and Lidbree indicated for various health issues related to men and women. The company sells products through its salesforce in Canada and licensed distributors in the US and other countries. Acerus is headquartered in Mississauga, Ontario, Canada.Acerus Pharmaceuticals Corp Key Recent Developments
Dec 26, 2022: Acerus Announces Resignation of DirectorNov 15, 2022: Acerus Reports Third Quarter 2022 Financial Results
Aug 23, 2022: Acerus Announces Resignation of CFO Effective November 20, 2022
Aug 09, 2022: Acerus Reports Second Quarter 2022 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Acerus Pharmaceuticals Corp - Key Facts
- Acerus Pharmaceuticals Corp - Key Employees
- Acerus Pharmaceuticals Corp - Key Employee Biographies
- Acerus Pharmaceuticals Corp - Major Products and Services
- Acerus Pharmaceuticals Corp - History
- Acerus Pharmaceuticals Corp - Company Statement
- Acerus Pharmaceuticals Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Acerus Pharmaceuticals Corp - Business Description
- R&D Overview
- Acerus Pharmaceuticals Corp - Corporate Strategy
- Acerus Pharmaceuticals Corp - SWOT Analysis
- SWOT Analysis - Overview
- Acerus Pharmaceuticals Corp - Strengths
- Acerus Pharmaceuticals Corp - Weaknesses
- Acerus Pharmaceuticals Corp - Opportunities
- Acerus Pharmaceuticals Corp - Threats
- Acerus Pharmaceuticals Corp - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Acerus Pharmaceuticals Corp, Recent Deals Summary
- Dec 26, 2022: Acerus Announces Resignation of Director
- Nov 15, 2022: Acerus Reports Third Quarter 2022 Financial Results
- Aug 23, 2022: Acerus Announces Resignation of CFO Effective November 20, 2022
- Aug 09, 2022: Acerus Reports Second Quarter 2022 Financial Results
- Jun 27, 2022: Acerus Announces Voting Results for the 2022 Annual Meeting
- May 10, 2022: Acerus Reports First Quarter 2022 Financial Results
- May 09, 2022: Acerus Pharmaceuticals Announces annual meeting of the holders
- Mar 15, 2022: Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
- Feb 18, 2022: Acerus announces amendment to loan facilities
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Acerus Pharmaceuticals Corp, Key Facts
- Acerus Pharmaceuticals Corp, Key Employees
- Acerus Pharmaceuticals Corp, Key Employee Biographies
- Acerus Pharmaceuticals Corp, Major Products and Services
- Acerus Pharmaceuticals Corp, History
- Acerus Pharmaceuticals Corp, Subsidiaries
- Acerus Pharmaceuticals Corp, Key Competitors
- Acerus Pharmaceuticals Corp, Ratios based on current share price
- Acerus Pharmaceuticals Corp, Annual Ratios
- Acerus Pharmaceuticals Corp, Interim Ratios
- Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Acerus Pharmaceuticals Corp, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Acerus Pharmaceuticals Corp, Performance Chart (2017 - 2021)
- Acerus Pharmaceuticals Corp, Ratio Charts
- Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Upsher-Smith Laboratories LLC
- Titan Medical Inc
- Paladin Labs Inc
- Merck Canada Inc
- Invaron Pharmaceuticals Inc
- Amgen Canada Inc
- Allergan Ltd
